Selective killing of cancer cells by Ashwagandha leaf extract and its component withanone involves ROS signaling

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Widodo, Nashi ^a,b   Priyandoko, Didik ^a,c   Shah, Navjot ^a,c   Wadhwa, Renu ^a   Kaul, Sunil C ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b BRAWIJAYA UNIVERSITY   (Indonesia)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A KINASE PRKA ANCHOR PROTEIN 11; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GENE PRODUCT; HAMMERHEAD RIBOZYME; HISTONE H2AX; INHIBITOR OF GROWTH FAMILY MEMBER 1; INSULIN; MICROTUBULE ASSOCIATED PROTEIN; PHYTOSTEROL; PROTEIN ING1; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR LHX3; UNCLASSIFIED DRUG; WITHAFERIN A; WITHANIA SOMNIFERA EXTRACT; WITHANONE; PLANT EXTRACT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL KILLING; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; GENE IDENTIFICATION; GENE LIBRARY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; MITOCHONDRIAL CRISTAE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL MORPHOLOGY; MITOCHONDRION; MITOCHONDRION SWELLING; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CHEMISTRY; DRUG EFFECT; METABOLISM; PLANT LEAF; TUMOR CELL LINE; WITHANIA; WITHANIA SOMNIFERA;

WITHANIA SOMNIFERA;

CELL LINE, TUMOR; HUMANS; PLANT EXTRACTS; PLANT LEAVES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; WITHANIA;

EID: 78149427794     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013536     Document Type: Article

References (43)

1. Modak M, Dixit P, Londhe J, Ghaskadbi S, Paul ADT (2007) Indian herbs and herbal drugs used for the treatment of diabetes. J Clin Biochem Nutr 40: 163-173.
2. Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5: 334-346.
3. Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern Med Rev 2006; 11: 269-77.
4. Deocaris CC, Widodo N, Wadhwa R, Kaul SC (2008) Merger of ayurveda and tissue culture-based functional genomics: inspirations from systems biology. J Transl Med 6: 14.
5. Tohda C (2008) Overcoming several neurodegenerative diseases by traditionalmedicines: the development of therapeutic medicines and unraveling patho-physiological mechanisms. Yakugaku Zasshi 128: 1159-1167.
6. Xu YM, Marron MT, Seddon E, McLaughlin SP, Ray DT, et al. (2009) 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A fromaeroponically grown Withania somnifera. Bioorg Med Chem 17: 2210-2214.
7. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazon J (2009) Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 14: 2373-2393.
8. Widodo N, Kaur K, Shrestha BG, Takagi Y, Ishii T, et al. (2007) Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumor-inhibitory factor and the first molecular insights to its effect. Clin Cancer Res 13: 2298-2306.
9. Widodo N, Takagi Y, Shrestha BG, Ishii T, Kaul SC, et al. (2008) Selective killing of cancer cells by leaf extract of Ashwagandha: Components, activity and pathway analyses. Cancer Lett 262: 37-47.
10. Widodo N, Shah N, Priyandoko D, Ishii T, Kaul SC, et al. (2009) Deceleration of senescence in normal human fibroblasts by withanone extracted from Ashwagandha leaves. J Gerontol A Biol Sci Med Sci 64: 1031-1038.
11. Tuschl T, Sharp PA, Bartel DP (1998) Selection in vitro of novel ribozymes from a partially randomized U2 and U6 snRNA library. EMBO J 17: 2637-2650.
12. Scott WG, Martick M, Chi YI (2009) Structure and function of regulatory RNA elements: ribozymes that regulate gene expression. Biochim Biophys Acta 1789: 634-641.
13. Usman N, Beigelman L, McSwiggen JA (1996) Hammerhead ribozyme engineering. Curr Opin Struct Biol 6: 527-533.
14. Yen L, Stockwell BR, Mulligan RC (2009) A mammalian cell-based assay for screening inhibitors of RNA cleavage. Methods Mol Biol 540: 335-347.
15. Wadhwa R, Yaguchi T, Kaur K, Suyama E, Kawasaki H, et al. (2004) Use of a randomized hybrid ribozyme library for identification of genes involved in muscle differentiation. J Biol Chem 279: 51622-51629.
16. Vlassov AV, Koval OA, Johnston BH, Kazakov SA (2004) ROLL: a method of preparation of gene-specific oligonucleotide libraries. Oligonucleotides 14: 210-220.
17. Welch PJ, Marcusson EG, Li QX, Beger C, Kruger M, et al. (2000) Identification and validation of a gene involved in anchorage-independent cell growth control using a library of randomized hairpin ribozymes. Genomics 66: 274-283.
18. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, et al. (1996) Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 70: 8782-8791.
19. Kim Y, Cairns MJ, Marouga R, Sun LQ (2003) E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes. Cancer Gene Ther 10: 707-716.
20. Unwalla HJ, Li H, Li SY, Abad D, Rossi JJ (2008) Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther 16: 1113-1119.
21. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, et al. (2006) AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25: 4831-4839.
22. Warner SL, Stephens BJ, Nwokenkwo S, Hostetter G, Sugeng A, et al. (2009) Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res 15: 6519-6528.
23. Bibby RA, Tang C, Faisal A, Drosopoulos K, Lubbe S, et al. (2009) A cancer- associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2. J Biol Chem 284: 33177-33184.
24. Tanenbaum ME, Macurek L, Janssen A, Geers EF, Alvarez-Fernandez M, et al. (2009) Kif15 cooperates with eg5 to promote bipolar spindle assembly. Curr Biol 19: 1703-1711.
25. Koinuma D, Tsutsumi S, Kamimura N, Taniguchi H, Miyazawa K, et al. (2009) Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling. Mol Cell Biol 29: 172-186.
26. Rajab A, Kelberman D, de Castro SC, Biebermann H, Shaikh H, et al. (2008) Novel mutations in LHX3 are associated with hypopituitarism and sensorineural hearing loss. Hum Mol Genet 17: 2150-2159.
27. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, et al. (2009) Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem 57: 477-489.
28. Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I (2009) ING proteins in cellular senescence. Curr Drug Targets 10: 406-417.
29. Shah S, Smith H, Feng X, Rancourt DE, Riabowol K (2009) ING function in apoptosis in diverse model systems. Biochem Cell Biol 87: 117-125.
30. Zhu Z, Luo Z, Li Y, Ni C, Li H, et al. (2009) Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology 49: 504-512.
31. Piccirillo S, Filomeni G, Brune B, Rotilio G, Ciriolo MR (2009) Redox mechanisms involved in the selective activation of Nrf2-mediated resistance versus p53-dependent apoptosis in adenocarcinoma cells. J Biol Chem 284: 27721-27733.
32. Ding H, Han C, Guo D, Chin YW, Ding Y, et al. (2009) Selective induction of apoptosis of human oral cancer cell lines by avocado extracts via a ROS- mediated mechanism. Nutr Cancer 61: 348-356.
33. Wu XJ, Hua X (2007) Targeting ROS: selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound. Cancer Biol Ther 6: 646-647.
34. Ge Y, Montano I, Rustici G, Freebern WJ, Haggerty CM, et al. (2006) Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood 108: 4126-4135.
35. Modica-Napolitano JS, Aprille JR (2001) Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49: 63-70.
36. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, et al. (2000) Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res 60: 6818-6821.
37. Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE (2008) Targeting mitochondria. Acc Chem Res 41: 87-97.
38. Lebedeva IV, Su ZZ, Sarkar D, Kitada S, Dent P, et al. (2003) Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res 63: 8138-8144.
39. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
40. Shah N, Kataria H, Kaul SC, Kaur G, Wadhwa R (2009) Effect of the alcoholic extract of Ashwagandha leaves and its components on proliferation and differentiation of glioblastoma cells: a combinational formula for enhanced differentiation. Cancer Sci 100: 1740-1747.
41. Mi H, Guo N, Kejariwal A, Thomas PD (2007) PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 35: D247-252.
42. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, et al. (2006) Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 34: W645-650.
43. Breitkreutz BJ, Stark C, Tyers M (2003) The GRID: the general repository for interaction datasets. Genome Biol 4: R23.